Energy drinks are often discussed through isolated medical cases, but a broader pattern emerges when dozens of cardiovascular studies are viewed together. New research from John Foy & Associates highlights a 2025 systematic review in which 63.2% of included studies reported QTc prolongation after energy drink consumption.
The pattern extends beyond heart rhythm. Researchers repeatedly documented changes in heart rate, blood pressure, and other electrocardiographic measures across the evidence base.
The review screened 1,444 energy drink references and ultimately analyzed 37 studies involving 1,597 participants, offering a wider clinical view than any single adverse-event report.
Key Findings
- 63.2% of the 37 included studies reported QTc interval prolongation after energy-drink consumption.
- 61.5% of studies reported increased diastolic blood pressure.
- 60.9% of studies reported increased heart rate.
- 57.9% of studies reported other ECG changes, including PR-interval and T-wave alterations.
- 53.8% of studies reported increased systolic blood pressure.
- 1,597 participants were represented across the 37 included studies.
- 22.6 years was the average participant age across the review.
Cardiovascular Effects Reported Across 37 Studies
| Cardiovascular Measure | Studies Reporting Effect | Evidence Context |
| QTc interval prolongation | 63.20% | Most frequently reported measured effect |
| Increased diastolic blood pressure | 61.50% | Blood-pressure response |
| Increased heart rate | 60.90% | Heart-rate response |
| Other ECG changes | 57.90% | Included PR-interval and T-wave changes |
| Increased systolic blood pressure | 53.80% | Blood-pressure response |
A Broader Clinical Picture Than Isolated Case Reports
The systematic review was led by U.S. researchers affiliated with Cleveland Clinic, MetroHealth, and Ohio University. Its 37 included studies covered 1,597 participants with an average age of 22.6 years, while Red Bull and Monster appeared most often among the energy-drink brands examined.
The percentages require careful interpretation. A finding that 63.2% of studies reported QTc prolongation does not mean 63.2% of individual consumers experienced that effect. The figures describe how often each cardiovascular change appeared across the included studies, not the proportion of people affected.
That distinction strengthens the medical value of the research rather than weakening it. The review does not claim that every energy-drink consumer will experience a cardiovascular problem. Instead, it shows that measurable cardiovascular changes appear repeatedly across independent studies using different participants and research settings.
What This Data Reveals
The strongest signal is consistency across different cardiovascular measures. Effects were not limited to heart rate or blood pressure, with researchers also reporting changes in electrical activity and other ECG markers.
The evidence also shows why isolated cardiac cases can oversimplify the issue. Systematic research points to measurable short-term cardiovascular changes, while the likelihood of a serious clinical outcome remains a separate question.
The review also highlights major gaps around long-term use, repeated exposure, and people with underlying vulnerabilities.
Why This Matters Now
Clinical evidence is accumulating while federal regulators are examining caffeine transparency. FDA placed caffeine-content labeling guidance on its 2026 agenda, creating a timely link between what researchers are measuring and what consumers are told about stimulant exposure.
For cardiovascular and medical-data reporters, the stronger story is not that energy drinks have been proven to cause heart disease. It is that measurable heart effects appear repeatedly across the literature, while important questions about individual risk remain unresolved.
Methodology
John Foy & Associates reviewed the findings of a 2025 U.S.-led systematic cardiovascular review that screened 1,444 references and included 37 eligible studies with 1,597 participants. The campaign also compares those findings with established clinical research on sudden cardiac arrest and a 2026 review examining cardiovascular risk factors associated with stimulant exposure.
Data Sources
- 2025 U.S.-led systematic review from researchers affiliated with Cleveland Clinic, MetroHealth, and Ohio University
- Mayo Clinic research involving 144 sudden cardiac arrest survivors
- 2026 clinical review examining energy drinks, cardiovascular susceptibility, and contextual risk factors
- FDA 2026 Human Foods Program materials concerning caffeine-content labeling
This article was created at the WHN News Desk in collaboration with Jackson Davis on behalf of John Foy & Associates, who pride themselves on their reputation for transparent, ethical action in representing their clients with catastrophic injury, wrongful death, workplace accidents, and defective drugs.
As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy of WHN. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything else. The Food and Drug Administration has not evaluated these statements.
